India's largest biopharmaceutical company Biocon decided to enter new areas of strategic business API. The development of varieties of bulk drugs, including ophthalmics, peptides, cytotoxics and MultipleSclerosis other drugs. Overall, demand for these drugs are in a period of rapid growth, and market access barriers are high. The company is trying to regulate the market of customers to obtain accreditation compliance, has submitted application materials received treatment for kidney disease drug drugs supply raw materials in emerging markets permission.
Vice president of marketing, Mr. AkashPuranik "Indian Pharmaceutical Information Network," describes the road, they have been purchased specifically for the production of new drug equipment. All the new drug has great potential in the global market needs, target markets, including emerging markets and mature markets in Europe and America. With technology-intensive nature of the API is its development focus. Its R & D experts through a variety of medical systems regulate the market master, and promote the establishment of a global business network, its high-tech, resveratrol high-quality production for the market acceptance, product mix and the ability to make one hundred health R & D company with a differentiated market competitiveness.
Eye API include latanoprost, travoprost, bimatoprost, dorzolamide and brinzolamide. According to R & D program, travoprost, bimatoprost, as a by reducing the intraocular pressure to control glaucoma and ocular hypertension prostaglandin analogues, the company is developing for the treatment of sterile ophthalmic solution drugs. Messe and were used to reduce stand out open-angle glaucoma and ocular hypertension in patients with intraocular pressure, chia seed the company is developing treatments for different degrees of sterile ophthalmic solution drugs. Brinzolamide is used to treat open-angle glaucoma and ocular hypertension and IOP carbonate inhibitor, the company is developing a suspension eye drops drugs. First quarter of 2011, its revenue of Rs 3.5428 billion, an increase of 7.7%. Other companies include the development of bulk drugs market continues to grow cholesterol-lowering drugs, fatty enzyme reversible inhibitors, immunosuppressants and anti-diabetic drugs.
Biopharmaceutical drugs are a class of materials with high growth new products, and market competition is not yet high, the appropriate product, technology and quality will soon form a differentiated production and management advantages. Preparation of pharmaceutical companies currently producing a new trend is to focus on economies of scale API production, the industry is to improve the level of basic capacity and increase R & D investment and the rapid introduction of new technology development stage.
As the Indian pharmaceutical companies have a high-tech professionals and the dual advantages of low price competition, thus forming a strong market opportunity driven, global production of chemicals and raw materials, drug companies are so keen to commission India are part of the production and research. Operating cost savings as part of measures to regulate the market, many multinational pharmaceutical raw materials companies have begun to seek cost-competitive source of bulk drugs, Indian firms are increasingly used as a preferred supplier of bulk drugs. Source:http://www.cospcn.com